Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Gore

Showing results (221-230 of 251) with videos related to

Pageof 26
Sort By:
Cancer Research|March 17, 2006
10th Biennial Helene Harris Memorial Trust meetingFrances R Balkwill, Alan Ashworth, Robert C Bast, et al.
Fertility and Sterility|June 13, 2022
Conception by fertility treatment and cardiometabolic risk in middle childhoodEdwina H Yeung, Pauline Mendola, Rajeshwari Sundaram, et al.
The American Journal of Clinical Nutrition|February 5, 2025
Relationship between gestational weight gain with fetal body composition and organ volumes in the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Fetal Dimensional Study: a prospective pregnancy cohortKathryn A Wagner, Zhen Chen, Stefanie N Hinkle, et al.
British Journal of Cancer|March 20, 2014
A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancerR M Glasspool, R Brown, M E Gore, et al.
Human Gene Therapy|June 12, 1999
Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanomaK Palmer, J Moore, M Everard, et al.
Oncotarget|April 29, 2017
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancerSaeed Rafii, Charlie Gourley, Rajiv Kumar, et al.
European Journal of Cancer (Oxford, England : 1990)|March 9, 2017
Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trialsAngela George, Rebecca Kristeleit, Saeed Rafii, et al.
American Journal of Obstetrics and Gynecology|May 5, 2016
Dichorionic twin trajectories: the NICHD Fetal Growth StudiesKatherine L Grantz, Jagteshwar Grewal, Paul S Albert, et al.
British Journal of Cancer|July 14, 2011
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studiesT Eisen, R Marais, A Affolter, et al.
BMJ Open|May 4, 2019
Diabetes & Women's Health (DWH) Study: an observational study of long-term health consequences of gestational diabetes, their determinants and underlying mechanisms in the USA and DenmarkCuilin Zhang, Sjurdur F Olsen, Stefanie N Hinkle, et al.
Pageof 26

Showing results (221-230 of 251) with videos related to

Sort By:
Pageof 26
Cancer Research|March 17, 2006
10th Biennial Helene Harris Memorial Trust meetingFrances R Balkwill, Alan Ashworth, Robert C Bast, et al.
Fertility and Sterility|June 13, 2022
Conception by fertility treatment and cardiometabolic risk in middle childhoodEdwina H Yeung, Pauline Mendola, Rajeshwari Sundaram, et al.
The American Journal of Clinical Nutrition|February 5, 2025
Relationship between gestational weight gain with fetal body composition and organ volumes in the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Fetal Dimensional Study: a prospective pregnancy cohortKathryn A Wagner, Zhen Chen, Stefanie N Hinkle, et al.
British Journal of Cancer|March 20, 2014
A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancerR M Glasspool, R Brown, M E Gore, et al.
Human Gene Therapy|June 12, 1999
Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanomaK Palmer, J Moore, M Everard, et al.
Oncotarget|April 29, 2017
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancerSaeed Rafii, Charlie Gourley, Rajiv Kumar, et al.
European Journal of Cancer (Oxford, England : 1990)|March 9, 2017
Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trialsAngela George, Rebecca Kristeleit, Saeed Rafii, et al.
American Journal of Obstetrics and Gynecology|May 5, 2016
Dichorionic twin trajectories: the NICHD Fetal Growth StudiesKatherine L Grantz, Jagteshwar Grewal, Paul S Albert, et al.
British Journal of Cancer|July 14, 2011
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studiesT Eisen, R Marais, A Affolter, et al.
BMJ Open|May 4, 2019
Diabetes & Women's Health (DWH) Study: an observational study of long-term health consequences of gestational diabetes, their determinants and underlying mechanisms in the USA and DenmarkCuilin Zhang, Sjurdur F Olsen, Stefanie N Hinkle, et al.
Pageof 26